Mustang Bio provides CFIUS update on facility sale to uBriGene; investigation due by May 13, 2024

MUSTANG BIO, INC.

Transaction involves sale of Worcester cell processing facility and manufacturing assets to uBriGene.
CFIUS review entered a second 45-day investigation period ending May 13, 2024.
CFIUS clearance not a condition to closing but may affect timing.

item 8.01

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-041199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.